Jaguar health provides corporate update and outlines 2022 milestones

2021 was a year of progress for jaguar health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (ctd) and short bowel syndrome with intestinal failure (sbs-if) and received conditional approval for canalevia™-ca1 (crofelemer) for dogs pipeline advancing in 2022 with company's phase 3 ctd study continuing and expected completion of an sbs-if investigator-initiated proof-of-concept trial 2022: jaguar's year of the dog with continued launch, education, and promotion activity for canalevia-ca1, which received conditional approval december 21, 2021, for chemotherapy induced diarrhea in dogs san francisco, ca / accesswire / january 13, 2022 / jaguar health, inc. (nasdaq:jagx) today provided a corporate update and outlined expected 2022 milestones. "2021 was a year of progress for jaguar health as we advanced our key human pipeline initiatives with the presentation at december's san antonio breast cancer symposium of phase 2 data for prophylaxis in chemotherapy-related diarrhea; received orphan drug designation in the european union for crofelemer for short bowel syndrome; formed napo therapeutics in milan, italy, which was subsequently funded as a result of the merger of napo therapeutics with milan-based dragon spac s.p.a.
JAGX Ratings Summary
JAGX Quant Ranking